Caprock Group LLC Purchases Shares of 1,049 Insulet Co. (NASDAQ:PODD)

Caprock Group LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,049 shares of the medical instruments supplier’s stock, valued at approximately $274,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its position in Insulet by 10.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock worth $202,000 after acquiring an additional 95 shares in the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Insulet in the 2nd quarter worth approximately $830,000. Czech National Bank raised its holdings in shares of Insulet by 7.0% in the 3rd quarter. Czech National Bank now owns 14,283 shares of the medical instruments supplier’s stock worth $3,324,000 after purchasing an additional 937 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Insulet by 26.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,683 shares of the medical instruments supplier’s stock worth $392,000 after purchasing an additional 347 shares in the last quarter. Finally, Mather Group LLC. boosted its holdings in Insulet by 74.0% during the third quarter. Mather Group LLC. now owns 816 shares of the medical instruments supplier’s stock worth $190,000 after buying an additional 347 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Raymond James increased their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Citigroup boosted their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $277.13.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $287.67 on Friday. Insulet Co. has a one year low of $160.19 and a one year high of $288.05. The business’s 50-day moving average price is $269.95 and its two-hundred day moving average price is $240.32. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market capitalization of $20.18 billion, a P/E ratio of 49.26, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same period in the prior year, the company posted $0.71 earnings per share. Analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.